Drug Safety Alliance Adds Pharmaceutical Veteran Deena B Wegner to Management Staff
Released on: September 2, 2008, 11:28 am
Press Release Author: David Menzies for Drug Safety Alliance
Industry: Biotech
Press Release Summary: (Research Triangle Park, N.C.) Drug Safety Alliance (DSA), a global leader in pharmaceutical safety and pharmacovigilance, has announced the addition of industry veteran Deena B. Wegner as vice president, business development and strategy.
Press Release Body: Wegner brings over 25 years of pharmaceutical and contact research organization experience to Drug Safety Alliance, having held senior leadership roles at Research Triangle Institute-Health Solutions, Integrated Safety Systems, Inc., and Berlex Laboratories. She is an active member of the Drug Information Association, Council for Entrepreneurial Development, and is Past President of the Healthcare Business Women’s Association RTP Chapter.
“Deena’s experience and passion for patient safety is a solid fit with our staff of healthcare professionals and experienced pharmacovigilance professionals,” Cathy Stokes, DSA president and CEO said. “Our vast experience in drug safety across the DSA team makes us unique in the industry and Deena will help us reach companies in need of global safety support, better IT options, and good risk mitigation and management strategies.”
Drug Safety Alliance assists in the development of drug safety plans that help pharmaceutical companies identify who should and should not use certain medications. In her new executive position, Wegner is responsible for DSA’s strategic planning and global partnerships and alliances, in addition to sales and marketing execution and new services positioning.
“Drug companies are taxed with the very complex and expensive process of maintaining information, reporting results, and conducting risk assessments for FDA and other agencies around the world. Most companies do not have internal expertise or the workforce to do this; that’s where DSA can help,” Wegner said. “All drugs carry risks, but by monitoring the adverse events , companies can identify trends and risk factors to ensure the drugs are used properly and in the right patients – that’s why it is so important to keep on top of the information.”
Wegner graduated from Tulane University with a B.S. in Biology.
About Drug Safety Alliance Founded in 2000, Drug Safety Alliance (DSA) provides pharmacovigilance expertise to large and small pharmaceutical and biotechnology companies to help them develop safe drugs and improve patient safety. DSA\'s mission is to partner with clients to mitigate their drug safety risks and to maximize product longevity and value. Driven by the highest ethical standards, DSA is uniquely focused to provide high-quality pre- and post-market drug safety services including domestic and international regulatory compliance, safety database support and hosting options, risk management and adverse event case management. DSA is headquartered in the Research Triangle Park region of North Carolina with strategic partnerships worldwide. For more information please visit www.DrugSafetyAlliance.com.
Web Site: http://www.drugsafetyalliance.com
Contact Details: David Menzies 105 Pinewood Dr. Apex, NC 27502 919-373-4274 dmenzies@menziesconsulting.com